Abstracts tagged "Health Assessment Questionnaire (HAQ)"

Abstract Number: 0145 • ACR Convergence 2020
Treat-to-Target in Rheumatoid Arthritis: Rates of Treatment Changes in Patients Engaged with Care Management Services Compared to Historically Reported National Registry Based Estimates
Pranav Patel¹, Andrew Krueger², Aliza Lipson³, Michele Hamburger⁴ and Craig Hunter⁵, ¹CVS Health, Toledo, OH, ²Accordant Health Services, Greensboro, NC, ³Emory University, Palmetto Bay, FL, ⁴Frances Hamburger Institute, Hauppauge, NY, ⁵CVS Health, Northbrook
Background/Purpose: Treat-to-target is the foundation of rheumatoid arthritis (RA) management. Prioritizing routine measurement of patient-reported disease activity along with conventional physician, laboratory and imaging assessments…
Abstract Number: 0153 • ACR Convergence 2020
Counseling on Safe Driving Strategies in Patients with Osteoarthritis and Rheumatoid Arthritis
Anna Falls¹, Peta-Gay Ricketts¹, John Elliott¹ and Kim Jordan¹, ¹OhioHealth Riverside Methodist Hospital, Columbus, OH
Background/Purpose: Osteoarthritis (OA) and rheumatoid arthritis (RA) cause functional impairments that impact daily life activities, including automobile driving. Radiographic presence of OA on knee and…
Abstract Number: 0329 • ACR Convergence 2020
Healthcare Utilization and Costs Associated with Functional Status in Patients with Psoriatic Arthritis
Alexis Ogdie¹, Mark Hwang², Phani Veeranki³, Alexandria Portelli³, Steven Sison³, Jason Shafrin³, Sofia Pedro⁴, Peter Hur⁵, Nina Kim⁶ and Kaleb Michaud⁷, ¹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ³PRECISIONheor, Los Angeles, ⁴FORWARD-The National Data Bank for Rheumatic Diseases, Wichita, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶The University of Texas at Austin; Baylor Scott and White Health, Austin, TX, ⁷FORWARD-The National Data Bank for Rheumatic Diseases; University of Nebraska Medical Center, Wichita
Background/Purpose: The Health Assessment Questionnaire Disability Index (HAQ-DI) has been validated and widely used in psoriatic arthritis (PsA) clinical trials for the assessment of patient…
Abstract Number: 0536 • ACR Convergence 2020
Systematic Geriatric Assessment in Older Patients with Rheumatic Diseases – The RheuMAGIC Pilot Study
Bjoern Buehring¹, Anna Berrisch², Ioana Andreica³, Styliani Tsiami⁴, David Kiefer³, Uta Kiltz², Xenofon Baraliakos² and Juergen Braun², ¹Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Velbert, Germany, ²Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany, ³Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, ⁴Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
Background/Purpose: Current demographic data predict that the number of older adults with rheumatic diseases will considerably increase in the coming years. Geriatric patients differ from…
Abstract Number: 0758 • ACR Convergence 2020
Anti-citrullinated Protein Antibodies Are Associated with Functional Disability in Unaffected First-degree Relatives of Rheumatoid Arthritis Patients
Dana Wiens¹, Irene Smolik¹, Xiaobo Meng¹, Vidyanand Anaparti¹, Hani El-Gabalawy¹ and Liam O'Neil¹, ¹University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: The preclinical stage of Rheumatoid Arthritis (RA) is characterized by seropositivity for anti-citrullinated protein antibodies (ACPA). We (PubMed ID 30861615), and others, have shown that ACPA seropositivity…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.